# Multimodal Biomarkers for Diagnosis and Prognosis in CAA

Study · id `cardio:ct-nct03969732` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03969732](<https://clinicaltrials.gov/study/NCT03969732>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03969732

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT03969732. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-09-27 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT03969732, source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)
- Started: 2018-09-27 (actual) (ClinicalTrials.gov record NCT03969732, source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)
- Primary completion: 2022-07-31 (anticipated) (ClinicalTrials.gov record NCT03969732, source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)
- Completion: 2022-07-31 (anticipated) (ClinicalTrials.gov record NCT03969732, source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT03969732, source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03969732-2021-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Multimodal Biomarkers for Diagnosis and Prognosis in CAA
- Acronym: CAA
- Condition: Cerebral Amyloid Angiopathy
- Condition: Intracranial Hemorrhages
- Condition: Alzheimer Disease
- Intervention (Drug): 1. amyloid PET；2. T807 PET
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)

## Provenance

Content hash: 7bb9eb3380995673e6fdf737584d2c57215f5dcb9151622ee9b9eccd5020f4e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
